Lipitor, Atorvastatin Newswire (Page 5)

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic). (Page 5)

Results 81 - 100 of 1,013 in Lipitor, Atorvastatin (generic)

  1. Sanofi and Regeneron report positive top-line results from nine phase ...Read the original story w/Photo

    Aug 1, 2014 | Medical News Today

    Sanofi and Regeneron Pharmaceuticals, Inc. have announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator.

    Comment?

  2. Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of AlirocumabRead the original story

    Jul 29, 2014 | Drugs.com

    July 30, 2014 - Sanofi and Regeneron Pharmaceuticals, Inc. today announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator.

    Comment?

  3. Lawsuit Funding For Lipitor and Crestor Diabetes LawsuitsRead the original story

    Jul 31, 2014 | PRWeb

    Lawsuit Funding Network has secured investors to assist victims who have developed Type-II Diabetes while either taking Lipitor or Crestor.

    Comment?

  4. Positive Results Reported From Nine Phase III Trials of Alirocumab in HypercholesterolemiaRead the original story

    Jul 30, 2014 | P&T Community

    Nine new phase III studies of alirocumab in patients with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared with placebo or an active comparator.

    Comment?

  5. Regeneron Pharmaceuticals, Inc., Sanofi (France) Drug Alirocumab Cuts ...Read the original story w/Photo

    Jul 30, 2014 | BioSpace

    Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia Primary Efficacy Endpoints Met In All Nine New Trials Of Investigational PCSK9 Inhibitor /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that nine new Phase 3 ODYSSEY trials of alirocumab in ... (more)

    Comment?

  6. New Cholesterol Drug Found to Work Better Than StatinsRead the original story

    Jul 30, 2014 | News Max

    Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

    Comment?

  7. Sanofi, Regeneron drug cuts cholesterol in nine late-stage trialsRead the original story

    Jul 30, 2014 | Reuters

    A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

    Comment?

  8. Pfizer's second-quarter profit sinks 79 percent but tops forecastsRead the original story

    Jul 29, 2014 | The Day

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion.

    Comment?

  9. Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice.Read the original story

    Jul 29, 2014 | CiteULike

    Atorvastatin is a statin largely used in the treatment of hypercholesterolemia and recently revealed as a neuroprotective agent.

    Comment?

  10. Pfizer's 2Q profit sinks 79% but tops forecastsRead the original story

    Jul 29, 2014 | Modern Healthcare

    Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.

    Comment?

  11. Pfizer's quarterly profit sank but topped forecastsRead the original story

    Jul 29, 2014 | Salt Lake Tribune

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.

    Comment?

  12. Pfizer's profit sinksRead the original story w/Photo

    Jul 29, 2014 | Iol.co.za

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion , but results in the most recent quarter still edged analyst expectations.

    Comment?

  13. Pfizer's profit sinks 79% yet still tops forecastsRead the original story

    Jul 29, 2014 | MSN Money

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion.

    Comment?

  14. Pfizer's Second Quarter Profit Sinks 79% But Tops ForecastsRead the original story w/Photo

    Jul 29, 2014 | Pharmaceutical Processing

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion, but results in the most recent quarter still edged analyst expectations.

    Comment?

  15. Drugmaker Pfizera s 2nd quarter profit sinks 79 per cent but still beats analyst expectationsRead the original story

    Jul 29, 2014 | 680News

    Pfizer's second-quarter earnings plunged 79 per cent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion, but results in the most recent quarter still edged analyst expectations.

    Comment?

  16. Generic usage increased to more than 75% in the UK in 2013 according to NHS dataRead the original story w/Photo

    Jul 29, 2014 | Medical News Today

    Usage of generic medicines in England and Wales increased to more than three-quarters of all NHS prescriptions in 2013 according to the latest figures supplied by the Health and Social Care Information Centre .

    Comment?

  17. Drugs to increase 'good' cholesterol may not cut deathsRead the original story w/Photo

    Jul 28, 2014 | Fox News

    Drugs that have been investigated to increase so-called "good" cholesterol may not prevent deaths, heart attacks or strokes as many hoped, according to a new analysis.

    Comment?

  18. Men who take statins may exercise lessRead the original story

    Jul 27, 2014 | The Times Bulletin

    Older men taking the cholesterol-lowering drugs known as statins appear to be slightly less active than those who don't take them, a new study suggests.

    Comment?

  19. Pfizer's Incoming Patent CliffRead the original story w/Photo

    Jul 24, 2014 | The Motley Fool

    The big pharma giant's loss of patent exclusivity on the world's former top-selling drug, cholesterol fighter Lipitor, has cost its drug revenues dearly.

    Comment?

  20. Hope rises for experimental drugs that lower cholesterolRead the original story w/Photo

    Mar 29, 2014 | WWLP

    A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a fresh option for people who can't tolerate or don't get enough help from Lipitor and other statin drugs that have been used for this for decades.

    Comment?